Non thyroidal illness syndrome
Conditions
Interventions
Subjects will receive protirelin (TRH) intravenously until the end of their
stay in the intensive care but with a minimum treatment duration of 5 days and
a maximum treatment duration of 2 weeks. Up
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Aged *18 Admitted to the ICU for at least 1 week prior to inclusion Expected duration of further stay *5 days Systemic treatment with morphine or other opioids
Exclusion criteria
Exclusion criteria: * Known pre-existing thyroid disease * Treatment with drugs aimed at restoring biochemical euthyroidsm (methimazole, propylthiouracil, triiodothyronine and levothyroxine) and amiodarone. * Treatment with heparine at a therapeutic (thrombolytic) dose (*10.000 IE/24h) * Treatment with somatostatin or dopaminergic drugs * Current glucocorticoid use or glucocorticoid use within *48 hours prior to study start * Renal failure requiring dialysis or hemofiltration * Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of the study is the change in T3 concentration after treatment with protireline. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoints of the study are thyroid hormone concentrations (T3, T4, fT4, rT3 and TSH), metabolic markers including urea, creatinine and the bone markers CTx and P1NP before, and during 1 and 2 weeks of treatment. | — |
Countries
Netherlands
Outcome results
None listed